Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 1

3141 - The final outcomes of study on combined therapy of adult patients with localized synovial sarcoma


28 Sep 2019


Poster Display session 1


Tumour Site



Katarzyna Kozak


Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283


K. Kozak1, I. Lugowska1, P. Teterycz1, H.M. Kosela Paterczyk2, T. Switaj1, T. Goryn1, W. Dziewirski1, T. Morysinski2, S. Falkowski2, P. Rutkowski3

Author affiliations

  • 1 Department Of Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska-Curie Institute - Oncology Center, 02-781 - Warsaw/PL
  • 2 Department Of Soft Tissue/bone Sarcoma And Melanoma, Maria Sklodowska Curie Institute - Oncology Centre (MSCI), 02-781 - Warsaw/PL
  • 3 Department Of Soft Tissue/bone Sarcoma And Melanoma, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3141


Synovial sarcoma is a high-grade, malignant soft tissue sarcoma (STS) considered as relatively chemosensitive tumor, with particular sensitivity to ifosfamide. The aim of this prospective study was to analyze outcomes of patients (pts) with localized synovial sarcoma treated in a single institution with uniform neo- and adjuvant combined therapy protocol.


One hundred and seventy one pts (96 women and 75 men) with localized synovial sarcoma were treated at our institution between 1997 and 2014. Chemotherapy consisted of 4 cycles of ifosfamide 12 g/m2 (2 cycles given preoperatively) and two cycles of doxorubicin-based regimen 75 mg/m2. Most pts received neoadjuvant hypofractionated radiation therapy followed by immediate surgery. At a median follow-up of 114 months (range, 3 to 244 months) 69 deaths were recorded.


Median age at diagnosis was 33 years (range 17-69). The most common localization was lower limb (n = 121), followed by upper limb (n = 32). Tumors larger than 5 cm in size were found in 70% of pts (median 8 cm; range 2 – 30 cm). Seventy-seven cases (45%) had primary diagnosed tumor. Sixty-four (37%) pts were referred to our institute after unplanned tumor excision and 30 (18%) pts because of clinical local recurrence. At the time of analysis, 36 (21%) pts had local recurrence (only 8% of pts with primary tumor) and 76 (44%) pts developed metastases. Median disease-free survival was 82 months. The 5-year overall survival (OS), local recurrence-free survival (LRFS) and distant recurrence-free survival (DRFS) rates were 74%, 80% and 60%, respectively. By univariate analysis, unplanned tumor excision (p = 0.0025) and positive margins (p = 0.048) were related to higher risk of local recurrence. In multivariable Cox’s regression, age >35 years (p = 0.045), male sex (p = 0.001), stage IIIB (p < 0.01) and histology other than monophasic (p = 0.033) were associated with worse OS.


In adult patients with localized synovial sarcoma, a long-term survival and local control can be achieved with intensive combined therapy. Our results confirms the importance of planned surgery and clear surgical margins for local control. We have demonstrated that age, sex, disease stage, and histology are independent prognostic factors of overall survival.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Poland.


Has not received any funding.


H.M. Kosela Paterczyk: Honoraria (institution): Novartis; Honoraria (self): MSD; Honoraria (self): BMS. P. Rutkowski: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: MSD; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Novartis; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution): BMS; Honoraria (self): Roche; Honoraria (self), Speaker Bureau / Expert testimony: Pfizer; Honoraria (self), Speaker Bureau / Expert testimony: Eli Lilly; Advisory / Consultancy: Blueprint Medicines. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.